Reprogramming cancer cells to pluripotency: An experimental tool for exploring cancer epigenetics

Epigenetics

Volumn 9, Issue 6, 2014, Pages 798-802

  Stricker, Stefan H ^a   Pollard, Steven M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; DNA methylation; Epigenetics; Glioblastoma; iPS cells; Neural stem cell; Polycomb; Reprogramming

Indexed keywords

ARTICLE; CANCER CELL; CARCINOGENICITY; DNA METHYLATION; DNA MODIFICATION; DNA REPLICATION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA; HUMAN; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; STEM CELL TRANSPLANTATION; ANIMAL; BRAIN TUMOR; CANCER STEM CELL; CARCINOGENESIS; CELL LINEAGE; GENETIC EPIGENESIS; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; NEURAL STEM CELL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; CELL LINEAGE; CELLULAR REPROGRAMMING; DNA METHYLATION; EPIGENESIS, GENETIC; GLIOBLASTOMA; HUMANS; INDUCED PLURIPOTENT STEM CELLS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASTIC STEM CELLS; NEURAL STEM CELLS;

EID: 84901745408     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.28600     Document Type: Article

References (49)

1. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150:12-27; PMID:22770212; http://dx.doi.org/10.1016/j. cell.2012.06.013
2. Carette JE, Pruszak J, Varadarajan M, Blomen VA, Gokhale S, Camargo FD, Wernig M, Jaenisch R, Brummelkamp TR. Generation of iPSCs from cultured human malignant cells. Blood 2010; 115:4039-42; PMID:20233975; http://dx.doi.org/10.1182/ blood-2009-07-231845
3. Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA. 2009 ed. 2010 Jan 5;107(1):40-5.
4. Stricker SH, Feber A, Engström PG, Carén H, Kurian KM, Takashima Y, Watts C, Way M, Dirks P, Bertone P, et al. Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev 2013; 27:654-69; PMID:23512659; http://dx.doi.org/10.1101/gad.212662.112
5. Kumano K, Arai S, Kurokawa M. Generation of iPS cells from normal and malignant hematopoietic cells. Int J Hematol. Springer Japan 2013; 98:145-52
6. Kim J, Hoffman JP, Alpaugh RK, Rhim AD, Reichert M, Stanger BZ, Furth EE, Sepulveda AR, Yuan CX, Won KJ, et al. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep 2013; 3:2088-99; PMID:23791528; http://dx.doi. org/10.1016/j.celrep.2013.05.036
7. Bird A. DNA methylation patterns and epigenetic memory. Genes & Development. Cold Spring Harbor Lab. 2002;16:6-21.
8. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301:89-92; PMID:6185846; http://dx.doi. org/10.1038/301089a0
9. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4:143-53; PMID:14732866; http://dx.doi.org/10.1038/ nrc1279
10. Barlow DP. Genomic imprinting: a mammalian epigenetic discovery model. Annu Rev Genet 2011; 45:379-403; PMID:21942369; http://dx.doi. org/10.1146/annurev-genet-110410-132459
11. Hackett JA, Reddington JP, Nestor CE, Dunican DS, Branco MR, Reichmann J, Reik W, Surani MA, Adams IR, Meehan RR. Promoter DNA methylation couples genome-defence mechanisms to epigenetic reprogramming in the mouse germline. Development 2012; 139:3623-32; PMID:22949617; http://dx.doi. org/10.1242/dev.081661
12. Walsh CP, Bestor TH. Cytosine methylation and mammalian development. Genes Dev 1999; 13:26-34; PMID:9887097; http://dx.doi.org/10.1101/ gad.13.1.26
13. Linhart HG, Lin H, Yamada Y, Moran E, Steine EJ, Gokhale S, Lo G, Cantu E, Ehrich M, He T, et al. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev 2007; 21:3110-22; PMID:18056424; http://dx.doi.org/10.1101/gad.1594007
14. Gao Q, Steine EJ, Barrasa MI, Hockemeyer D, Pawlak M, Fu D, Reddy S, Bell GW, Jaenisch R. Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl Acad Sci U S A 2011; 108:18061-6; PMID:22011581; http://dx.doi.org/10.1073/pnas.1114946108
15. Beck S, Rakyan VK. The methylome: approaches for global DNA methylation profiling. Trends Genet 2008; 24:231-7; PMID:18325624; http://dx.doi. org/10.1016/j.tig.2008.01.006
16. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet. 2010; 11:191-203
17. Meissner A. Epigenetic modifications in pluripotent and differentiated cells. Nat Biotechnol 2010; 28:1079-88; PMID:20944600; http://dx.doi. org/10.1038/nbt.1684
18. Ji H, Ehrlich LIR, Seita J, Murakami P, Doi A, Lindau P, Lee H, Aryee MJ, Irizarry RA, Kim K, et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010; 467:338-42; PMID:20720541; http://dx.doi. org/10.1038/nature09367
19. Bestor TH. Unanswered questions about the role of promoter methylation in carcinogenesis. Ann N Y Acad Sci 2003; 983:22-7; PMID:12724209; http:// dx.doi.org/10.1111/j.1749-6632.2003.tb05959.x
20. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007; 39:237-42; PMID:17211412; http://dx.doi. org/10.1038/ng1972
21. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007; 39:157-8; PMID:17200673; http://dx.doi.org/10.1038/ng1941
22. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7:21-33; PMID:16369569; http://dx.doi. org/10.1038/nrg1748
23. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013; 13:497-510; PMID:23760024; http://dx.doi.org/10.1038/ nrc3486
24. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013; 153:38-55; PMID:23540689; http://dx.doi.org/10.1016/j. cell.2013.03.008
25. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j. cell.2011.02.013
26. Leitch HG, Smith A. The mammalian germline as a pluripotency cycle. Development. The Company of Biologists Limited 2013; 140:2495-501
27. Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. Nature 2010; 465:704-12; PMID:20535199; http://dx.doi. org/10.1038/nature09229
28. Hochedlinger K, Plath K. Epigenetic reprogramming and induced pluripotency. Development 2009; 136:509-23; PMID:19168672; http://dx.doi. org/10.1242/dev.020867
29. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. Isolation and characterization of tumorigenic, stemlike neural precursors from human glioblastoma. Cancer Res 2004; 64:7011-21; PMID:15466194; http://dx.doi.org/10.1158/0008-5472.CAN-04-1364
30. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9:391-403; PMID:16697959; http://dx.doi.org/10.1016/j. ccr.2006.03.030
31. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009; 4:568-80; PMID:19497285; http:// dx.doi.org/10.1016/j.stem.2009.03.014
32. Engström PG, Tommei D, Stricker SH, Ender C, Pollard SM, Bertone P. Digital transcriptome profiling of normal and glioblastoma-derived neural stem cells identifies genes associated with patient survival. Genome Med 2012; 4:76; PMID:23046790; http:// dx.doi.org/10.1186/gm377
33. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, Ropero S, Schackert G, Esteller M. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009; 4:255-64; PMID:19550145
34. Blelloch RH, Hochedlinger K, Yamada Y, Brennan C, Kim M, Mintz B, Chin L, Jaenisch R. Nuclear cloning of embryonal carcinoma cells. Proc Natl Acad Sci U S A 2004; 101:13985-90; PMID:15306687
35. Hochedlinger K, Blelloch R, Brennan C, Yamada Y, Kim M, Chin L, et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes & development 2004; 18:1875-85.
36. Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol 2008; 6:e253.
37. Pollard SM, Benchoua A, Lowell S. Neural stem cells, neurons, and glia. Methods in enzymology 2006; 418:151-69.
38. Conti L, Pollard SM, Gorba T, Reitano E, Toselli M, Biella G, et al. Niche-independent symmetrical selfrenewal of a mammalian tissue stem cell. PLoS Biol 2005; 3:e283.
39. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40:499-507.
40. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010; 143:313-24.
41. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 2006; 66:3541-9; PMID:16585178; http:// dx.doi.org/10.1158/0008-5472.CAN-05-2481
42. Sproul D, Nestor C, Culley J, Dickson JH, Dixon JM, Harrison DJ, Meehan RR, Sims AH, Ramsahoye BH. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci U S A 2011; 108:4364-9; PMID:21368160; http://dx.doi. org/10.1073/pnas.1013224108
43. Sproul D, Kitchen RR, Nestor CE, Dixon JM, Sims AH, Harrison DJ, Ramsahoye BH, Meehan RR. Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biol 2012; 13:R84; PMID:23034185; http://dx.doi. org/10.1186/gb-2012-13-10-r84
44. Schwartzentruber J, Korshunov A, Liu X-Y, Jones DTW, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482:226-31; PMID:22286061; http://dx.doi.org/10.1038/ nature10833
45. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, et al.; St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012; 44:251-3; PMID:22286216; http://dx.doi.org/10.1038/ ng.1102
46. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, Wang X, Gallo M, Garzia L, Zayne K, et al. Epigenomic alterations define lethal CIMPpositive ependymomas of infancy. Nature 2014; 506:445-50; PMID:24553142; http://dx.doi. org/10.1038/nature13108
47. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009; 9:773-84; PMID:19851313; http:// dx.doi.org/10.1038/nrc2736.
48. Obokata H, Wakayama T, Sasai Y, Kojima K, Vacanti MP, Niwa H, Yamato M, Vacanti CA. Stimulustriggered fate conversion of somatic cells into pluripotency. Nature 2014; 505:641-7; PMID:24476887; http://dx.doi.org/10.1038/nature12968
49. Di Stefano B, Sardina JL, van Oevelen C, Collombet S, Kallin EM, Vicent GP, Lu J, Thieffry D, Beato M, Graf T. C/EBPα poises B cells for rapid reprogramming into induced pluripotent stem cells. Nature 2014; 506:235-9; PMID:24336202; http://dx.doi. org/10.1038/nature12885